Stockpolly
Search
TECX · NASDAQ · Biotechnology

Tectonic Therapeutic (TECX)

Develops GPCR-targeted biologics for pulmonary vascular and rare vascular diseases.

$30.39
Pre-market+0.01 (+0.03%)
At close$30.38(−2.69%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
10913112014182222222724
Research & development87117149131717162118
222455555566
General & administrative222455555566
Operating income−10−9−13−11−20−14−18−22−22−22−27−24
02−2−122233322
Interest income000022233322
Interest expense000000000000
Other non-operating income0−221−2−2−2−3−3−3−2−2
Income before tax−10−8−15−13−18−12−16−19−19−19−25−22
Income tax expense000000010000
Net income from continuing operations−10−8−15−13−18−12−16−20−19−19−25−22
Net income−10−8−15−13−18−12−16−20−19−19−25−22
EPS, basic−$0.68−$2.36−$1.82−$4.34−$1.20−$0.84−$0.93−$1.07−$1.02−$1.03−$1.34−$1.18
EPS, diluted−$0.68−$2.36−$1.82−$4.34−$1.20−$0.84−$0.93−$1.07−$1.02−$1.03−$1.34−$1.18
Weighted average shares, basic444151515171919181919
Weighted average shares, diluted444151515171919181919
EBITDA−10−7−15−12−17−12−16−19−19−18−25−22
Depreciation & amortization000001000100
EBIT−10−8−15−13−18−12−16−19−19−19−25−22